Morgan Ebert, Managing Editor

GSK, Spero Therapeutics, resubmitted an NDA for tebipenem HBr, an oral carbapenem antibiotic, for treating complicated UTIs, supported by phase 3 trial data.

ASCO’s new guideline outlines evidence-based strategies for diagnosing and treating leukemia and lymphoma during pregnancy.

The FDA approved flibanserin for HSDD in women younger than 65 years, expanding access to the first nonhormonal therapy for low sexual desire.

The FDA has approved Nuzolvence as a new single-dose oral option for uncomplicated urogenital gonorrhea in adults and children 12 years and older who weigh at least 77 lb.

Phase 3 results show oral zoliflodacin was non-inferior to ceftriaxone and azithromycin for uncomplicated urogenital gonorrhea.

This approval of gepotidacin is the first in a new antibiotic class for the treatment of gonorrhoea approved in over 3 decades.

A phase 2 trial found the maternal GBS-AlpN vaccine to be immunogenic and have an acceptable safety profile in pregnant women and their infants.

DARE to PLAY sildenafil cream is now available for prescribing in select states as a non-hormonal topical option to improve genital blood flow and arousal.

Large US cohort finds women with uterine fibroids had more than 80% higher 10-year cardiovascular disease risk than women without fibroids.

ACS updates cervical cancer screening guidance, adding HPV self-collection and clarifying criteria for safely discontinuing screening at older ages.

A randomized trial found that real-time continuous glucose monitoring reduced large-for-gestational-age births compared with self-monitoring in gestational diabetes.

Higher maternal vitamin D levels in pregnancy were associated with reduced odds of early childhood caries and lower DMFT scores in offspring.

Discontinuing GLP-1 receptor agonists before or early in pregnancy was associated with greater gestational weight gain and higher risks of diabetes, hypertension, and preterm birth.

Take a quick look at everything you may have missed in November, including the latest FDA updates, top stories, and expert recommendations.

Holiday meals carry extra food safety risks for pregnant patients. Here’s what ob-gyns should remind them before Thanksgiving gatherings.

Planned community births in Oregon showed increased risks only when hospital transfer occurred, underscoring the need for clear counseling and transfer systems.

A US study of women over 60 found that frequent sex toy use during masturbation was strongly associated with higher orgasm frequency.

Two-thirds of pregnancies fall outside recommended gestational weight gain ranges, increasing risks for adverse maternal and neonatal outcomes.

Closed-loop insulin delivery improved time in pregnancy-specific glucose range in a randomized trial of individuals with type 1 diabetes.

Study finds trouble sleeping, sleep apnea, and short or long sleep duration are linked to higher odds of hypertension in postmenopausal women.

Survey reveals limited allergy referrals in pregnancy due to lack of guidance and long wait times, highlighting need for better education.

Higher waist-to-hip ratio was linked to poorer cognitive performance in early postmenopause, though it did not alter hormone therapy effects.

FDA updates labeling for menopausal hormone therapy, removing broad boxed warnings and adding guidance for younger symptomatic patients.

Elective egg freezing increased nearly 4-fold from 2014 to 2021, but only 5.7% of women later returned to use their frozen oocytes.

Take a quick look at everything you may have missed in October, including the latest FDA updates, top stories, and exclusive interviews.

Research at The Menopause Society 2025 meeting highlighted safety, education, and individualized care in menopause management.

Earlier menopause accelerates memory decline in women with APOE ε4 or inflammation, highlighting sex-specific Alzheimer disease risk factors.

A systematic review found estrogen-based hormone therapy did not consistently reduce anxiety or depression in midlife women.

A new study finds that earlier menopause and reduced cardiac function may together worsen brain health, highlighting dementia risk factors.

Women with early natural menopause face a 27% higher risk of metabolic syndrome, underscoring the need for early cardiometabolic screening.